Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from ...
Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...
Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.
Remicade (infliximab) is a prescription drug that’s used to treat certain autoimmune conditions, such as rheumatoid arthritis. Remicade can cause side effects that range from mild to serious. Examples ...
First-line treatment of fecal microbiota transplantation for immune-mediated colitis. First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and ...
Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...
Birmingham, UK - Although infliximab (Remicade, Centocor) was licensed for use in the treatment of ankylosing spondylitis (AS) in Europe nearly 2 years ago, in the UK there has been little experience ...
Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of ...
MALVERN, Pa.--(BUSINESS WIRE)--Dec. 20, 2004--Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE(R) (infliximab) for the treatment of ankylosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results